Home » Market News » DirectorsTalk Highlights » New stem cell treatment uses umbilical cord blood for bone marrow patients
WideCells Group PLC

New stem cell treatment uses umbilical cord blood for bone marrow patients

A treatment that uses stem cells from umbilical cord blood could be safe for bone marrow transplant patients, a study says.

The findings of a new study, published Tuesday in the Journal of Clinical Oncology, show that 94% of adult patients with blood cancers who received the umbilical cord blood treatment ended up with successful graft procedures within six weeks.

“Although umbilical cord blood transplantation has been used for 30 years, expansion technology represents an opportunity to improve the results for adult patients,” said Mitchell Horwitz, professor of medicine at Duke and lead author of the study, in a news release.

 

Widecells Group PLC (LON:WDC) are leading a transformation in cord blood banking and stem cell treatment; making cord blood banking more accessible through insurance coverage, and increasing the availability of cord blood for transplants.

To read the full news article please click here

Receive our exclusive interviews – Enter your email to stay up to date.

Disclaimer: Statements in this article should not be considered investment advice, which is best sought directly from a qualified professional.